Trials / Completed
CompletedNCT01878123
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis
A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, single-dose, placebo-controlled, dose-escalation,multi-center, first time in human study of AMP-110 in adult subjects with rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AMP-110 | Dose levels 1 through 7: Single intravenous infusion on Day 0 |
| OTHER | Placebo | Dose levels 4 through 7: Single intravenous infusion on Day 0 |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2013-06-14
- Last updated
- 2016-09-30
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01878123. Inclusion in this directory is not an endorsement.